ReviewBlood2008
Whole genome scanning as a cytogenetic tool in hematologic malignancies.
Review in Blood, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives.Cancers · 2024Review
- Genome-wide identification of copy neutral loss of heterozygosity reveals its possible association with spatial positioning of chromosomes.Human molecular genetics · 2023Article
- Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia.Diagnostics (Basel, Switzerland) · 2023Review
- Whole-genome sequencing as a first-tier diagnostic framework for rare genetic diseases.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- The prognostic significance of single-nucleotide polymorphism array-based whole-genome analysis and uniparental disomy in myelodysplastic syndrome.International journal of laboratory hematology · 2021Article
- Article
- SNPs Array Karyotyping in Non-Hodgkin Lymphoma.Microarrays (Basel, Switzerland) · 2015Review
- Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?The oncologist · 2015Review
- I walk the line: how to tell MDS from other bone marrow failure conditions.Current hematologic malignancy reports · 2014Article
- The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.The oncologist · 2014Review
- Cryptic chromosome abnormalities in a patient with mixed phenotype acute leukemia.Leukemia & lymphoma · 2014Article
- Polymorphisms in microRNA-related genes are associated with survival of patients with T-cell lymphoma.The oncologist · 2014Article
- The Biology and Targeting of FLT3 in Pediatric Leukemia.Frontiers in oncology · 2014Review
- Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia.Current cancer drug targets · 2013Review
- Single-nucleotide polymorphism-array improves detection rate of genomic alterations in core-binding factor leukemia.Medical oncology (Northwood, London, England) · 2013Article
- Additional chromosomal abnormalities detected by array comparative genomic hybridization in AML.Medical oncology (Northwood, London, England) · 2012Article
- CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors.Leukemia · 2012Article
- Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.Journal of hematology & oncology · 2012Article
- Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis.Molecular cytogenetics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the years, methods of cytogenetic analysis evolved and became part of routine laboratory testing, providing valuable diagnostic and prognostic information in hematologic disorders. Karyotypic aberrations contribute to the understanding of the molecular pathogenesis of disease and thereby to rational application of therapeutic modalities. Most of the progress in this field stems from the application of metaphase cytogenetics (MC), but recently, novel molecular technologies have been introduced that complement MC and overcome many of the limitations of traditional cytogenetics, including a need for cell culture. Whole genome scanning using comparative genomic hybridization and single nucleotide polymorphism arrays (CGH-A; SNP-A) can be used for analysis of somatic or clonal unbalanced chromosomal defects. In SNP-A, the combination of copy number detection and genotyping enables diagnosis of copy-neutral loss of heterozygosity, a lesion that cannot be detected using MC but may have important pathogenetic implications. Overall, whole genome scanning arrays, despite the drawback of an inability to detect balanced translocations, allow for discovery of chromosomal defects in a higher proportion of patients with hematologic malignancies. Newly detected chromosomal aberrations, including somatic uniparental disomy, may lead to more precise prognostic schemes in many diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.